Ma et al. 33 recently demonstrated that, LRSL treatment upregulated annexin A1, which can affect the formation and activity of protein complexes upstream of the MAPK signaling pathway in HepG2 cells, thereby contribute to the anticancer activity in liver cancer cell. This evidence concerns the gene ANXA1 and liver cancer.